Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843611 | 1.00 | L3MBTL1 (0.52) | L3MBTL1IDO1TDO2IP6K1KDM4E | |
| SCHEMBL14658864 | 0.89 | L3MBTL1 (0.43) | L3MBTL1IDO1TDO2IP6K1KDM4E | |
| SCHEMBL30820850 | 0.89 | L3MBTL1 (0.43) | L3MBTL1IDO1TDO2IP6K1KDM4E | |
| SCHEMBL29520198 | 0.80 | DYRK1A (0.42) | IDO1TDO2EGFRLPLLIPG | |
| SCHEMBL13028373 | 0.80 | DYRK1A (0.42) | IDO1TDO2EGFRLPLLIPG | |
| SCHEMBL3261262 | 0.78 | IDO1 (0.48) | IDO1TDO2EGFRPRMT5WDR77 | |
| SCHEMBL29843596 | 0.78 | ACVR1 (0.49) | L3MBTL1IDO1TDO2KDM4EACVR1 | |
| SCHEMBL29520345 | 0.77 | GRM5 (0.42) | KDM4EALDH1A1HPGDHSD17B10LPL | |
| SCHEMBL13028375 | 0.77 | GRM5 (0.42) | KDM4EALDH1A1HPGDHSD17B10LPL | |
| SCHEMBL19356377 | 0.75 | IDO1 (0.42) | IDO1TDO2EGFRPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3840748-B1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12077548-B2 | Substituted imidazoles for the inhibition of TGF-β and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2024-09-03 | — | — | US | disclosed |
| WO-2022078403-A1 | SUBSTITUTED PYRIDONE COMPOUND AND APPLICATION | 江苏先声药业有限公司 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078403-A1 | SUBSTITUTED PYRIDONE COMPOUND AND APPLICATION | 江苏先声药业有限公司 | 2022-04-21 | — | — | WO | disclosed |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-03 | — | — | US | disclosed |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-03 | — | — | US | disclosed |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2021-09-21 | — | — | US | disclosed |
| EP-3840748-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC | 2020-07-30 | — | — | US | disclosed |
| WO-2020041562-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020041562-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2020-02-27 | — | — | WO | disclosed |
| WO-2019005241-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS, LLC (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-2417121-A1 | 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | Pfizer Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010116282-A1 | 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010020366-A1 | AZABICYCLIC SUBSTITUTED 5-AMINOPYRAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020366-A1 | AZABICYCLIC SUBSTITUTED 5-AMINOPYRAZOLES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077548-B2 | Substituted imidazoles for the inhibition of TGF-β and methods of treatment | TGFB1, TGFBR1, TGFB2 | L3MBTL1 1657/4885IDO1 70/4885TDO2 2995/4885 |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | GLS, GLS2, TK2 | L3MBTL1 3196/4885IDO1 1640/4885TDO2 3272/4885 |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | L3MBTL1 2519/4885IDO1 317/4885TDO2 2625/4885 |
| US-20220064187-A1 | SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | L3MBTL1 1536/4885IDO1 57/4885TDO2 2864/4885 |
| US-20200239462-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | L3MBTL1 2519/4885IDO1 317/4885TDO2 2625/4885 |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NR3C2, REN, AGTR1 | L3MBTL1 4869/4885IDO1 4243/4885TDO2 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.